Catalyst Wire Dossier Catalyst Wire Dossier

Brivekimig

· Sanofi
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Brivekimig, covering 2026-04-08 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease [Phase 2]

See pricing